Related Experiment Video
Updated: Aug 15, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
Published on: July 3, 2025
FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase
Chieko Mineo1, Andrew K Gormley, Ivan S Yuhanna
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Insights
C-reactive protein (CRP) impairs endothelial nitric oxide synthase (eNOS) activation, promoting monocyte adhesion and endothelial dysfunction. This mechanism involves FcgammaRIIB and protein phosphatase 2A (PP2A).
Area of Science:
- Cardiovascular Biology
- Immunology
- Cellular Signaling
Background:
- C-reactive protein (CRP) is linked to cardiovascular disease risk and endothelial dysfunction.
- The direct effects of CRP on the endothelium and their underlying mechanisms remain unclear.
Purpose of the Study:
- To investigate the direct actions of CRP on endothelial cells.
- To elucidate the molecular mechanisms by which CRP influences endothelial function.
Main Methods:
- Experiments using cultured endothelial cells to assess eNOS activation and monocyte adhesion.
- Investigating the role of protein phosphatase 2A (PP2A) and FcgammaRIIB receptor.
- Utilizing FcgammaRIIB knockout mice to study in vivo effects.
Main Results:
- CRP inhibits endothelial nitric oxide synthase (eNOS) activation by reducing phosphorylation at Ser1179.
- CRP-induced eNOS inhibition is mediated by FcgammaRIIB and requires PP2A activity.
- In vivo, CRP impairs acetylcholine-induced vascular responses in wild-type mice but not in FcgammaRIIB knockout mice.
Conclusions:
- CRP directly impairs endothelial function by inhibiting eNOS activation through the FcgammaRIIB-PP2A pathway.
- This provides a mechanistic link between CRP, FcgammaRIIB, and endothelial dysfunction.
- Targeting this pathway may offer therapeutic strategies for cardiovascular diseases.
Abstract:
C-reactive protein (CRP) is an acute-phase reactant that is positively correlated with cardiovascular disease risk and endothelial dysfunction. Whether CRP has direct actions on endothelium and the mechanisms underlying such actions are unknown. Here we show in cultured endothelium that CRP prevents endothelial NO synthase (eNOS) activation by diverse agonists, resulting in the promotion of monocyte adhesion. CRP antagonism of eNOS occurs nongenomically and is attributable to blunted eNOS phosphorylation at Ser1179. Okadaic acid or knockdown of PP2A by short-interference RNA reverses CRP antagonism of eNOS, indicating a key role for the phosphatase. Aggregated IgG, the known ligand for Fcgamma receptors, causes parallel okadaic acid-sensitive loss of eNOS function, FcgammaRIIB expression is demonstrable in endothelium, and heterologous expression studies reveal that CRP antagonism of eNOS requires FcgammaRIIB. In FcgammaRIIB(+/+) mice, CRP blunts acetylcholine-induced increases in carotid artery vascular conductance; in contrast, CRP enhances acetylcholine responses in FcgammaRIIB(-/-) mice. Thus FcgammaRIIB mediates CRP inhibition of eNOS via PP2A, providing a mechanistic link between CRP and endothelial dysfunction.
Related Concept Videos
Nitric Oxide Signaling Pathway
GPCRs Regulate Adenylyl Cylase Activity
Two...
GPCR Desensitization
G-Protein Gated Ion Channels
Sensory organs,...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
